A Clinician's Guide to Navigating COVID-19 (Favipiravir, Remdesivir)

COVID-19 Treatment: Drug Dosages for Adults and Children

This table summarizes the indications and dosages of key drugs used for treating COVID-19 in both adults and children.

---

Introduction

The COVID-19 pandemic continues to present challenges to healthcare systems worldwide. While widespread vaccination and evolving scientific knowledge have improved patient outcomes, the virus's unpredictable nature requires clinicians to remain current on the latest management strategies. This comprehensive guide provides internal medicine and pediatric residents with up-to-date, practical recommendations for diagnosing, treating, and managing COVID-19, including specific drug dosages.

---

I. Diagnosis: Identifying Suspect Cases

Accurate and timely diagnosis is crucial for effective COVID-19 management. Suspect the infection in any patient presenting with these clinical or epidemiological features:

A. Clinical Criteria (Adults and Children):

• At least 2 of the following: Fever, cough, nasal congestion/discharge, sore throat, sputum production.
• One of the above symptoms PLUS one of the following: Diarrhea, muscle aches, headache, nausea/vomiting, fatigue, rash.
• Any of the following: Dyspnea, shortness of breath, anosmia/ageusia, confusion, decreased consciousness.
• Severe respiratory tract infection: Pneumonia on imaging or ARDS.
• Physician suspicion of COVID-19.
• Recent contact with a confirmed COVID-19 case.

B. Laboratory Diagnosis:

• Reverse Transcription Polymerase Chain Reaction (RT-PCR): Remains the gold standard for confirming SARS-CoV-2 infection.
• Antigen Tests: Offer rapid results with good sensitivity and specificity, particularly in symptomatic patients. Useful for initial screening and point-of-care testing.
• Antibody Tests: Not recommended for diagnosis due to potential for false negatives early in infection and variability in antibody response.

---

II. Severity Assessment: Risk Stratification for Optimized Management

After confirming COVID-19, assess the patient's risk for severe disease to guide treatment decisions.

A. Asymptomatic Infection:

• No specific treatment is required.
• Emphasize public health measures: isolation, masking, hand hygiene.

B. Mild to Moderate Disease (No Pneumonia):

• Outpatient management: Supportive care with over-the-counter medications for symptom relief.
• Risk factor assessment for potential progression to severe disease is crucial:
  • Age: 60 years or older.
  • Comorbidities: COPD, CKD stage 3+, cardiovascular disease, stroke, diabetes, obesity (BMI ≥ 30 kg/m²), cirrhosis, cancer, immunosuppression (including HIV with CD4 < 200 cells/mm³, transplant recipients, and those on immunosuppressive medications).

C. Moderate to Severe Disease (Pneumonia and/or Hypoxemia):

• Hospitalization is often required: Consider oxygen therapy, respiratory support, and close monitoring.
• Pharmacotherapy:
  • Antiviral agents:
    • Remdesivir:
    • Adults: 200 mg IV on Day 1, followed by 100 mg IV daily for 4 days (total 5 days). For severe disease, consider extending to 10 days.
    • Pediatrics: 5 mg/kg IV on Day 1, followed by 2.5 mg/kg IV daily for 5-10 days.
      • Nirmatrelvir/Ritonavir (Paxlovid): Nirmatrelvir 300 mg (two 150 mg tablets) with Ritonavir 100 mg (one 100 mg tablet) given orally twice daily for 5 days. Dose adjustments are required for renal impairment.
      • Molnupiravir: 800 mg (four 200 mg capsules) orally twice daily for 5 days.
  • Corticosteroids:
    • Dexamethasone: 6 mg IV or orally once daily for up to 10 days. Dosage may be adjusted based on clinical response and severity of illness.
  • Other therapies:
    • Tocilizumab (IL-6 inhibitor): Weight-based dosing: 8 mg/kg IV (max single dose 800 mg) over 1 hour; may repeat once after 8-12 hours if clinically indicated.
    • Baricitinib (JAK inhibitor): 2 mg or 4 mg orally once daily for up to 14 days (dose depends on clinical severity and concurrent medications).
    • Tofacitinib (JAK inhibitor): 5 mg orally twice daily for up to 14 days or until hospital discharge (whichever occurs first).

---

III. Pediatric Considerations

Management largely mirrors adult guidelines, with adjustments for pediatric dosages.

Favipiravir:

• Dosage:
  • Children >3 months to <18 years:
    • Day 1: 60 mg/kg/day PO bid.
    • Subsequent Days: 20 mg/kg/day PO bid.
• Precautions: Not recommended for pregnant and breastfeeding women due to potential teratogenic effects.

Multisystem Inflammatory Syndrome in Children (MIS-C):

• High index of suspicion: Fever, rash, gastrointestinal symptoms, and multi-organ involvement weeks after acute COVID-19.
• Management:
  • Intravenous immunoglobulin (IVIG): 2 g/kg as a single infusion over 10-12 hours. May repeat if no response.
  • Corticosteroids:
    • Methylprednisolone: 2 mg/kg/day IV divided every 6 hours (maximum 60 mg/day).
    • Dexamethasone: 0.15 mg/kg/day IV divided every 12 hours (maximum 6 mg/day). Taper dose as clinically indicated.
  • Aspirin: Low-dose aspirin (3-5 mg/kg/day, maximum 81 mg/day) is often used unless contraindicated (e.g., thrombocytopenia).

---

IV. Managing COVID-19 in Specific Patient Populations

A. Pregnancy:

• Higher risk for severe disease: Requires vigilant monitoring and early intervention.
• Remdesivir: Considered the preferred antiviral agent in most trimesters. Dosage as for adults.
• Nirmatrelvir/Ritonavir: Use with caution; potential for drug interactions and limited data. Consult specialists. Dosage as for adults.
• Molnupiravir: Contraindicated due to potential teratogenicity.

B. Kidney Disease:

• Remdesivir: Dose adjustments are required for patients with eGFR < 30 mL/min. Consult renal dosing guidelines.
• Nirmatrelvir/Ritonavir: Dosage adjustments are needed based on eGFR levels and dialysis status. Consult renal dosing guidelines.

C. Liver Disease:

• Remdesivir: Monitor liver function closely. No specific dose adjustments.
• Nirmatrelvir/Ritonavir: Use with caution in moderate to severe liver disease. Consult specialists. Dosage as for adults.

---

V. Post-Infection Management and Long COVID

A. Discharge and Isolation:

• Symptom-based criteria: Most patients can be discharged after clinical improvement, regardless of test results.
• Continue isolation precautions for at least 5 days after symptom onset, followed by strict masking for an additional 5 days.

B. Long COVID:

• Persistent symptoms beyond 4 weeks: Fatigue, dyspnea, cognitive impairment, and other debilitating symptoms.
• Management: Multidisciplinary approach involving primary care, specialists, and rehabilitation services.

---

Conclusion

This guide offers a practical framework for managing COVID-19 in various clinical settings, including specific drug dosages to aid in informed decision-making. However, each patient's care must be individualized based on their unique circumstances, comorbidities, and risk factors. Continuous learning, collaboration with experienced colleagues, and open communication with patients and families are paramount in navigating the complexities of this pandemic.